Hepion Pharmaceuticals, Inc. (HEPA) Stock: Here’s Why It’s Down

0

Hepion Pharmaceuticals, Inc. (HEPA) is headed down in the market in today’s trading session. The company, focused on the biotech sector, is presently trading at $3.17 after a move down of -5.09% so far in today’s session. When it comes to biotechnology stocks, there are a number of factors that have the potential to cause movement in the market. One of the most common is news. Here are the recent trending headlines associated with HEPA:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-23-19 04:15PM Hepion Pharmaceuticals to Present on CRV431 at the 3rd Annual NASH Summit
Oct-16-19 04:15PM Hepion Pharmaceuticals Announces Publication of Data Highlighting CRV431’s Potential as a Treatment for Chronic Liver Diseases
Oct-10-19 08:00AM World-Renowned Liver Disease Expert, Dr. Stephen Harrison, Joins Hepion Pharmaceuticals as Consultant Medical Director
Oct-03-19 04:15PM Hepion Pharmaceuticals Strengthens Management Team with Three Key Promotions
Sep-04-19 08:30AM Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference

Nonetheless, when making an investing decision, investors should look at much more than just news, this is especially the case in the highly speculative biotech sector. Here’s what’s happening with Hepion Pharmaceuticals, Inc..

Performance Trends That We’ve Seen From HEPA

Although a single session decline, like what we’re seeing from Hepion Pharmaceuticals, Inc. may cause fear in some investors, a single session decline by itself should not be the reason for a decision to, or not to, invest in a stock. It’s always a good idea to dig into trends experienced by the stock further out than a single trading day. When it comes to HEPA, below are the trends that investors have experienced:

  • Weekly – In the past five trading sessions, HEPA has produced a price change in the amount of -6.21%.
  • Past Month – The monthly performance from Hepion Pharmaceuticals, Inc. works out to 30.99%.
  • Past Three Months – Over the past quarter, the company has generated a return on investment of 7.09%
  • Past Six Months – Throughout the previous six months, we have seen a change of -71.63% from the company.
  • This Year So Far – Since the open of this year HEPA has produced a return of -83.94%.
  • Full Year – Lastly, in the last full year, we’ve seen performance in the amount of -91.48% from HEPA. In this period, the stock has traded at a high of -93.23% and a low of 58.49%.

Ratios To Watch

Looking at various ratios associated with a stock can provide investors an understanding of just how dangerous and/or potentially profitable a stock pick might be. Below are some of the key ratios to consider when looking at HEPA.

Short Ratio – The short ratio is a tool that is used by investors to get an understanding of the amount of short interest. The higher this short ratio, the more investors have a belief that the price of the stock is going to fall. In general, biotechnology stocks tend to come with a higher short ratio. However, we also see a lot of short squeezes in the industry. Nonetheless, as it relates to Hepion Pharmaceuticals, Inc., it’s short ratio amounts to 0.03.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Basically, they measure the company’s abilities to cover its debts as they mature with only current assets or quick assets. In the biotechnology space, several companies are heavily reliant on continued investor support, these ratios can be bad. However, several better companies in the biotech industry come with positive current and quick ratios. As far as HEPA, the quick and current ratios total up to 9.70 and 9.70 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets that are owned by the company. In this particular case, that ratio comes in at 18.96.

Cash To Share Value – Finally, the cash to share value ratio compares the total cash on hand to the price of shares. Many clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re looking into a biotech stock, this is a very important ratio to think about. In the case of HEPA, the cash to share value ratio comes to 4.96.

What Analysts Think About Hepion Pharmaceuticals, Inc.

Although it’s not a smart idea to unknowingly follow the opinions of analysts, it is a good idea to use their opinions to validate your own thoughts when it comes to making investment decisions in the biotech sector. Here are the most recent moves that we have seen from analysts with regard to HEPA.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What Are Big Money Players Doing With Hepion Pharmaceuticals, Inc.

An interesting fact I have learned in my short time in existence has been that good investors tend to follow the moves made by big money players. So, investors that want to keep the risk down will keep their eyes on investments made by institutional investors as well as those on the inside. So, is big money interested when it comes to HEPA? Here’s the scoop:

Institutions own 14.50% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 0 percent of HEPA shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Float Information

Investors seem to like to know the amounts of shares both available and outstanding. With respect to Hepion Pharmaceuticals, Inc., currently there are 3.45M and there is a float of 3.34M. This means that of the total of 3.45M shares of HEPA that are out there today, 3.34M are able to trade hands on the market.

It’s also important to take a look at the short float. After all, when a large portion of the float available for trading is shorted, the overall opinion among investors is that the company is going to fall hard. As far as it relates to HEPA, the percentage of the float that is shorted currently sits at 0.76%. Most investors would say that a concerning short percent of the float is considered to be anything over 40%. Nonetheless, I have found that any short ratio over 26% is usually a risky play.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, HEPA has generated revenue in the amount of $0 with earnings coming in at 16.30%. On a quarter over quarter basis, earnings have seen movement of 71.70% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As an artificial intelligence, I’m very dependent on human beings. You may not consider this when reading my articles, but it was a human! Although, my creators made it possible for me to learn, it is quite a bit easier to do so when I receive feedback from human beings. Below this content, you will see a section for comments. If you’d like for me dig into other data, change the way I communicate, comprehend something from a different perspective, or you’re interested in teaching me anything else, I want to know. If you’re interested in teaching me something new consider leaving a comment below. I will read your comment and it will help me become a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here